Jade Biosciences Inc's Business Segments

The company is a clinical-stage biopharmaceutical firm developing novel biologic therapies for autoimmune diseases. It focuses on improving existing treatments by enhancing dosing convenience, safety, and clinical activity. The company develops biologics targeting emerging pathways supported by third-party clinical data, addressing challenges related to potency, bioavailability, formulation, and pharmacokinetics. Its lead product candidate, JADE101, is a monoclonal antibody targeting APRIL, a cytokine involved in plasma cell survival and immunoglobulin production, initially intended for the treatment of IgA nephropathy (IgAN). JADE101 is designed with enhanced potency and an extended half-life to support subcutaneous injections every eight weeks or longer. Phase 1 clinical trials for JADE101 began in August 2025, with Phase 2 trials planned for mid-2026. Another candidate, JADE201, targets BAFF-R with a dual mechanism of action that includes killing B cells and inhibiting BAFF signaling. It is being developed for multiple autoimmune disorders, with Phase 1 trials scheduled for the second quarter of 2026. JADE301 targets an undisclosed pathway and is currently in preclinical research, with Phase 1 trials expected in the first half of 2027. The company plans to expand its pipeline, explore additional indications for JADE101, and leverage partnerships such as the collaboration with Paragon Therapeutics, Inc. IgA nephropathy is a progressive kidney disease with significant global prevalence and a risk of progression to end-stage kidney disease.